Chroma Medicine Presents Data Demonstrating Benefits of Epigenetic Editing for Multigene Regulation at ASGCT 2023

Simultaneous epigenetic editing of three genes in primary human T cells produced no indels or genomic alterations, whereas simultaneous triple editing with Cas9 nuclease resulted in profound chromosomal aberrations.

boston, May 19, 2023 /PRNewswire/ — saturation medicineInc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapy, today presented data demonstrating the benefits of epigenetic editing in multigene regulation at the American Society for Gene and Cell Therapy (ASGCT) 26th annual meeting Los Angeles.

Chroma’s epigenetic editing platform harnesses the cell’s endogenous machinery to control gene expression to permanently regulate transcription without cutting or damaging DNA, making it safer for multiple editing. may offer a different approach. This avoids the challenges associated with gene-editing methods that rely on DNA breaks to alter gene expression that can introduce unnecessary risks, such as chromosomal rearrangements when multiplexing multiple genes simultaneously. .

Data presented today at ASGCT demonstrate significant advantages of epigenetic editing in multigene regulation compared to Cas9-based approaches. Applying Chroma’s epigenetic editor to three different genes simultaneously achieved sustained silencing in primary human T cells. Sequencing and single-cell imaging assays showed that multiple epigenetic editing did not induce indels, chromosomal rearrangements, or other unintended genomic alterations compared to controls. Conversely, cells co-edited using the Cas9 nuclease showed a significant number of translocations and other inadvertent violations of genome integrity.

“These results highlight one of the key advantages of harnessing nature’s innate mechanisms for precise gene regulation: by regulating expression without cutting DNA, multiple Genes can be targeted safely and efficiently at the same time.” Vic Mayer, Ph.D., President and CSO of Chroma. “Given together with results published yesterday demonstrating sustained and highly efficient silencing of PCSK9 and hepatitis B virus, these data validate our platform and its distinct advantages in the use of epigenetic editing treatments. We are well positioned to advance the broader pipeline of law.”

“The data presented by Chroma and our scientific founders at ASGCT represent an important step toward rapidly bringing these medicines to patients.” Catherine Steman-Breen, MD, MS, CEO of Chroma. “We are committed to rigorously advancing pioneering epigenetic editing technologies and programs, supporting the therapeutic potential of epigenetic editing for gene regulation while preserving genome integrity. We are pleased to present the data.”

Details of Chroma’s upcoming oral presentations at ASGCT include:

title: Multiple editing without chromosomal rearrangement using epigenetic editors
Presenter: Sahar AbbakarSenior Director of Data Science
Date and time: Friday, May 19thth4:45 PM PT
session: Genome and epigenome editing technology

Chroma’s presentation will be available on the company’s website after the conference.

About Chromamedicine

Chroma Medicine is developing a new class of genomic medicines that harness nature’s innate mechanisms for gene regulation, epigenetics, to deliver precise, programmable single-dose therapies while preserving genomic integrity. A pioneering biotech company. The company was founded by the world’s leading experts in genomics research and is led by a seasoned team of industry leaders and scientists with deep experience in genomic medicine, drug discovery and development. For more information, visit or follow the company on LinkedIn and Twitter.

Source Chromamedicine

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *